Video

Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia

Author(s):

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Diseases like polycythemia vera and essential thrombocythemia are unique, says Mesa, as they are malignancies, but a lot of patients have very long survival. However, some can progress.

Mesa states that the primary goal of the guidelines is the avoidance of thrombosis and bleeding in a risk-based fashion.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Francine Foss, MD
Daniel DeAngelo, MD, PhD
Daniel DeAngelo MD, PhD, professor, medicine, Harvard Medical School; physician, chief, Division of Leukemia, Dana-Farber Cancer Institute
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.